# Patient Organization Collaboration Framework

**Document Version**: 1.0
**Last Updated**: November 9, 2025
**Owner**: Executive Director & Patient Advocacy Director
**Purpose**: Comprehensive framework for establishing, managing, and sustaining collaborative relationships with other rare disease patient organizations‚Äîenabling resource sharing, coalition building, joint advocacy, and amplified patient impact while maintaining Foundation's distinct identity and mission focus.

---

## üìã Table of Contents

1. [Collaboration Philosophy](#collaboration-philosophy)
2. [Types of Patient Organization Partners](#types-of-patient-organization-partners)
3. [Partnership Models](#partnership-models)
4. [Collaboration Agreements](#collaboration-agreements)
5. [Resource Sharing Arrangements](#resource-sharing-arrangements)
6. [Coalition Building](#coalition-building)
7. [Joint Advocacy Campaigns](#joint-advocacy-campaigns)
8. [Patient Data Sharing](#patient-data-sharing)
9. [Cross-Promotional Strategies](#cross-promotional-strategies)
10. [Conflict Resolution](#conflict-resolution)
11. [Partnership Sustainability](#partnership-sustainability)
12. [Budget & Resources](#budget--resources)

---

## Collaboration Philosophy

### Why Collaborate with Other Patient Organizations?

**Reality**: Rare disease organizations face common challenges‚Äîlimited funding, small staff, fragmented patient populations, lack of political clout.

**Strength in Numbers**: Collaborating with similar organizations creates:
- ‚úÖ **Amplified advocacy**: 10 rare disease orgs asking Congress together > 10 orgs asking separately (collective voice carries weight)
- ‚úÖ **Resource efficiency**: Share infrastructure (database platforms, fundraising tools, legal templates‚Äîavoid duplicating costs)
- ‚úÖ **Knowledge exchange**: Learn from peers ("How did you get pharmaceutical partnership? What worked/didn't in patient registry?"‚Äîaccelerate Foundation's learning curve)
- ‚úÖ **Patient cross-referrals**: AATD patient might also have primary immunodeficiency (overlap diagnosis)‚Äîpartner with PI foundation, cross-refer patients to appropriate resources

---

### Core Collaboration Values

**1. Mission Complementarity, Not Competition**
- ‚úÖ Partner with organizations serving similar populations (lung disease, genetic conditions, rare diseases) or sharing advocacy goals (research funding, diagnostic access)
- ‚ùå Don't compete for same donors/patients (e.g., two AATD organizations in same region‚Äîwasteful duplication, better to merge or collaborate)

**2. Mutual Benefit**
- ‚úÖ Win-win partnerships (both organizations gain‚Äîresources, visibility, patient value)
- ‚ùå One-sided "partnerships" where larger org extracts value from smaller org (Foundation gets used for mailing list, receives nothing back‚Äîexploitative)

**3. Identity Preservation**
- ‚úÖ Collaboration ‚â† merger (Foundation maintains AATD focus, distinct brand, independent governance)
- ‚úÖ Clear attribution ("This event co-sponsored by Mark Egly Foundation and [Partner]"‚Äîboth names visible, credit shared)

**4. Transparency & Communication**
- ‚úÖ Open communication (quarterly check-ins, shared Google Docs, responsive emails‚Äîavoid "ghost partner" syndrome)
- ‚úÖ Honest feedback ("Your annual report template helped us‚Äîthank you!" or "We're struggling with X‚Äîany advice?"‚Äîvulnerability builds trust)

---

## Types of Patient Organization Partners

### 1. Direct Peer Organizations (Same Disease)

**Profile**: Organizations serving AATD patients (few exist‚ÄîU.S. has 2-3 major AATD orgs, Europe/Canada have 1-2 each).

**Collaboration Opportunities**:
- **Non-compete agreements**: Divide territories (Foundation focuses East Coast, partner focuses West‚Äîreduce patient/donor confusion)
- **Joint research**: Pool patient data (combine registries ‚Üí larger sample sizes, more robust studies)
- **Shared services**: Split costs for AATD educational materials (co-develop brochure, both orgs distribute‚Äîhalve design/printing costs)
- **Merger discussions** (Long-term): If missions identical, consolidate (more efficient to have one strong AATD org than two struggling ones‚Äîbut politically difficult, ego/control issues)

**Example Partners**: Alpha-1 Foundation (largest U.S. AATD org), AlphaNet (patient services, disease management), Canadian Alpha-1 Foundation

**Relationship Complexity**: üî¥ HIGH (potential competition for donors, patients‚Äîrequires careful boundary-setting)

---

### 2. Related Disease Organizations

**Profile**: Organizations serving patients with overlapping conditions (COPD, pulmonary fibrosis, primary ciliary dyskinesia‚Äîall lung diseases, similar symptoms/treatments to AATD).

**Collaboration Opportunities**:
- **Cross-referrals**: COPD patient discovers they have AATD (genetic test)‚ÄîCOPD foundation refers to Mark Egly Foundation for AATD-specific support
- **Joint educational events**: Co-host webinar ("Genetic Causes of Lung Disease"‚ÄîAATD, cystic fibrosis, PCD covered), split costs, share audience
- **Advocacy coalitions**: Jointly lobby for lung disease research funding (NIH allocation), diagnostic access (insurance coverage for genetic testing)

**Example Partners**: COPD Foundation, Pulmonary Fibrosis Foundation, American Lung Association, Cystic Fibrosis Foundation

**Relationship Complexity**: üü° MODERATE (complementary missions, minimal competition, but need to educate patients on disease differences)

---

### 3. Rare Disease Coalitions

**Profile**: Umbrella organizations representing 200-400 rare disease patient groups (collective advocacy, shared resources, amplified voice).

**Collaboration Opportunities**:
- **Membership benefits**: Join coalition (annual dues $1K-$5K), gain access to‚Äîshared legal templates, fundraising webinars, policy updates, peer networking
- **Collective advocacy**: Coalition organizes "Rare Disease Day" (February 28), Hill visits (100+ rare disease orgs meet Congress together‚Äîpowerful optics), social media campaigns (#RareIsStrong‚Äîtrending hashtags)
- **Discounted services**: Coalition negotiates bulk discounts (insurance, database platforms, legal services‚Äîmember orgs save 10-30%)

**Example Partners**: National Organization for Rare Disorders (NORD), Global Genes, EveryLife Foundation (policy advocacy), Genetic Alliance

**Relationship Complexity**: üü¢ LOW (no competition‚Äîumbrella org supports all rare diseases, not specific to AATD)

---

### 4. International Patient Organizations

**Profile**: AATD patient organizations in other countries (Europe, Canada, Australia, Latin America‚ÄîAATD is global).

**Collaboration Opportunities**:
- **Global awareness campaigns**: Coordinate World AATD Day (hypothetical‚ÄîFoundation establishes, international partners amplify), social media campaign reaches millions globally
- **Research partnerships**: International patient registries (combine U.S. + European + Canadian data ‚Üí 10,000+ patients, unprecedented statistical power)
- **Cross-border patient support**: U.S. patient moving to Germany‚ÄîFoundation connects them to German AATD organization (warm handoff)

**Example Partners**: Alpha-1 UK, Alpha-1 Deutschland (Germany), Australian Alpha-1 Association, Asociaci√≥n Alfa-1 Espa√±a (Spain)

**Relationship Complexity**: üü° MODERATE (language barriers, time zones, differing healthcare systems, but no donor competition‚ÄîU.S. foundation doesn't compete for European donors)

---

## Partnership Models

### 1. Informal Collaboration

**Definition**: Ad hoc cooperation (no formal contract)‚Äîmutual support, resource sharing, occasional joint activities.

**Examples**:
- Foundation shares blog post from partner org ("Great article on COPD genetics from our friends at COPD Foundation")
- Reciprocal newsletter mentions ("Know someone with AATD? Check out Mark Egly Foundation")
- Informal advice ("How did you structure your patient registry? Can we see your consent form?"‚Äîpeer learning)

**Pros**: ‚úÖ Flexible, low commitment, easy to start
**Cons**: ‚ùå No accountability (partner may forget about collaboration), no guaranteed resources

**When to Use**: Early-stage relationship-building (test compatibility before formal partnership)

---

### 2. Memorandum of Understanding (MOU)

**Definition**: Written agreement outlining collaboration goals, roles, expectations‚Äînot legally binding (unlike contract), but creates accountability.

**Examples**:
- **Joint event**: Foundation + COPD Foundation co-host webinar ("Lung Disease Genetics")‚ÄîMOU specifies: Foundation handles logistics (Zoom, registration), COPD Foundation provides speaker, both orgs promote, costs split 50/50
- **Resource sharing**: Foundation and Alpha-1 Foundation agree to share patient education materials (both can use each other's brochures, fact sheets‚Äîavoid duplicating work)

**Pros**: ‚úÖ Clear expectations, accountability, low legal risk (not contract)
**Cons**: ‚ùå Not enforceable (if partner reneges, no legal recourse‚Äîrely on goodwill)

**When to Use**: Medium-term collaborations (6-24 months), project-specific (event, campaign), where trust exists but formality helps

---

### 3. Formal Partnership Agreement

**Definition**: Legally binding contract‚Äîdetailed terms, obligations, dispute resolution, termination clauses.

**Examples**:
- **Data sharing**: Foundation and European AATD org sign agreement to combine patient registries‚Äîcontract specifies data security, IRB approval, publication rights, IP ownership (legally complex ‚Üí formal contract needed)
- **Co-branded program**: Foundation and pharma-funded nonprofit co-develop patient assistance program‚Äîcontract defines roles, liability, termination (risk of misalignment ‚Üí legal protection needed)

**Pros**: ‚úÖ Enforceable, protects both parties, clear dispute resolution
**Cons**: ‚ùå Legal costs ($2K-$5K), time-consuming (3-6 months to negotiate), inflexible (amendments require both parties' consent)

**When to Use**: Long-term collaborations (3+ years), high-value/high-risk (data sharing, financial commitments >$25K), complex multi-party agreements

---

## Collaboration Agreements

### Memorandum of Understanding (MOU) Template

**MEMORANDUM OF UNDERSTANDING**

**Between**: Mark Egly Foundation ("MEF") and [Partner Organization] ("Partner")

---

**1. PURPOSE**

MEF and Partner recognize shared mission of improving lives of patients with rare genetic conditions. This MOU establishes framework for collaboration to:
- Amplify patient education and awareness
- Share resources and expertise
- Jointly advocate for policy improvements
- Foster rare disease community connections

---

**2. COLLABORATION ACTIVITIES**

**Year 1 (2026) Specific Activities**:

**A. Joint Webinar Series** (Quarterly):
- **Topic**: Genetic Lung Diseases (AATD, Cystic Fibrosis, Primary Ciliary Dyskinesia)
- **Format**: 60-minute webinar (45-min presentation, 15-min Q&A), Zoom platform
- **Roles**:
  - MEF: Provide Zoom account, handle registration, moderate Q&A, secure CME accreditation (if applicable)
  - Partner: Recruit 1-2 speakers (pulmonologists, genetic counselors), promote to their mailing list (5,000 contacts)
- **Cost Sharing**: Split speaker honoraria 50/50 ($500 total, $250 each org), each org covers own promotion costs
- **Branding**: Co-branded slides ("Presented by Mark Egly Foundation & [Partner]"), both logos equal size

**B. Resource Exchange**:
- MEF shares: Patient education brochures (PDF‚ÄîAATD 101, Genetic Testing Guide), patient registry platform technical specs
- Partner shares: Fundraising event toolkit (templates, checklists, sample sponsorship prospectuses), social media content calendar

**C. Cross-Promotion**:
- Each org mentions the other in monthly newsletter (1 paragraph + link‚Äîdrive traffic to partner's resources)
- Social media shout-outs (2-3√ó/year‚Äî"Check out [Partner]'s new guide on X")

---

**3. GOVERNANCE**

**Point of Contact**:
- **MEF**: [Executive Director, email, phone]
- **Partner**: [Executive Director, email, phone]

**Quarterly Check-Ins**:
- Video call (30-60 minutes) to review progress, address challenges, plan next quarter activities
- First meeting: March 2026, then June, September, December

**Decision-Making**:
- Consensus-based (both orgs must agree on joint activities‚Äîif disagree, table until next meeting)
- No unilateral decisions (e.g., MEF can't announce joint event without Partner's consent)

---

**4. FINANCIAL TERMS**

**Funding**: No money exchanged between organizations (each org funds its own contributions‚Äîstaff time, promotional costs).

**Shared Expenses** (If Any):
- Event costs (venue rental, catering, printing) split 50/50‚Äîboth orgs invoice their half within 30 days
- Joint fundraising (if pursued): Revenue split per agreed formula (e.g., 50/50, or proportional to donor source‚Äî"MEF recruited $10K, Partner recruited $15K ‚Üí MEF gets 40%, Partner gets 60%")

---

**5. INTELLECTUAL PROPERTY**

**Joint Creations**: Any materials co-developed (webinar slides, brochures, toolkits) are jointly owned‚Äîboth orgs may use freely (no restrictions, no royalties).

**Existing IP**: Each org retains ownership of pre-existing materials (MEF's brochures remain MEF's, Partner's toolkit remains Partner's)‚Äîbut grant each other non-exclusive license to use (can distribute each other's materials with attribution).

---

**6. CONFIDENTIALITY**

**Non-Confidential**: This collaboration is public (both orgs may announce partnership, promote jointly).

**Confidential Info**: If either org shares confidential information (donor lists, patient identifiable data, proprietary strategies), recipient will protect confidentiality‚Äînot disclose to third parties without written consent.

---

**7. TERM & TERMINATION**

**Term**: January 1, 2026 - December 31, 2026 (12 months, renewable by mutual agreement)

**Termination**:
- Either party may terminate with 60 days written notice (no penalty, no explanation required‚Äî"no-fault divorce")
- Upon termination: Complete any in-progress joint activities (e.g., if webinar scheduled for 30 days post-termination, both orgs follow through), then cease new collaborations

**Renewal**: 90 days before expiration, parties discuss renewal‚Äîif both agree, sign new MOU for next year (may update activities, terms).

---

**8. LEGAL STATUS**

**Non-Binding**: This MOU is statement of intent and goodwill, not a legally binding contract. Either party may modify or terminate at any time (per Section 7).

**Independence**: This MOU does not create partnership, joint venture, agency, or employment relationship‚Äîeach org remains independent 501(c)(3) with separate governance, finances, liabilities.

---

**9. SIGNATURES**

**Mark Egly Foundation**:
_________________________________
[Executive Director Name]
Date: ___________

**[Partner Organization]**:
_________________________________
[Executive Director Name]
Date: ___________

---

## Resource Sharing Arrangements

### What Resources to Share

**Knowledge & Expertise**:
- **Best practices**: Fundraising strategies, volunteer management, social media tactics (peer learning‚Äî"Here's what worked for us, try adapting for your org")
- **Templates**: Grant proposals, sponsorship letters, policy briefs (save time‚Äîdon't reinvent wheel)
- **Staff expertise**: Foundation's CMO guest lectures at partner's webinar (cross-pollinate knowledge, audiences benefit from diverse perspectives)

**Physical Resources**:
- **Mailing lists** (With Permission): Foundation shares patient mailing list with COPD Foundation for cross-promotional campaign‚Äîonly if patients opt in ("May we share your contact with partner organizations?"‚ÄîHIPAA/privacy compliance)
- **Event spaces**: If Foundation rents conference room (seats 100, expects 50 attendees), offer unused space to partner org (efficient use of resources, build goodwill)
- **Equipment**: Foundation owns portable spirometers (for patient education)‚Äîloan to partner org for their event (mutual equipment sharing reduces costs)

**Financial Resources**:
- **Bulk purchasing**: Foundation + 3 partner orgs jointly purchase database platform (negotiate group discount‚Äî$5K/org instead of $7K individually)
- **Shared legal counsel**: Foundation + partner orgs hire same nonprofit attorney (retainer shared‚Äî$10K/year split 5 ways = $2K each, vs. $5K individually)
- **Joint grant applications**: Apply to foundations as coalition ("Five rare disease orgs collaborating on X"‚Äîfunders like collaboration, may unlock larger grants than single org could win)

---

### Resource Sharing Agreement Template

**RESOURCE SHARING AGREEMENT**

**Between**: Mark Egly Foundation and [Partner Organization]

---

**1. SHARED RESOURCES**

**MEF Provides to Partner**:
- Patient education brochures (PDF format‚ÄîAATD 101, Genetic Testing Guide, Treatment Options)
- Social media content calendar template (Excel file‚Äîpost schedule, content themes, engagement tactics)
- Access to MEF's Zoom Pro account (up to 10 webinars/year, 100 participant limit‚ÄîPartner books in advance)

**Partner Provides to MEF**:
- Fundraising event toolkit (templates, checklists, sample sponsorship prospectuses)
- Introduction to Partner's design contractor (discounted rate‚Äî$80/hour vs. $120 retail)
- Access to Partner's CRM platform (5 user licenses‚ÄîMEF staff can use for 1-year trial, decide if to purchase separately)

---

**2. TERMS OF USE**

**Attribution**:
- Materials must be attributed ("Adapted from [Originating Org]")‚Äîrespect intellectual property, give credit
- Cannot remove original org's logo/branding without permission (if MEF's brochure has MEF logo, Partner can't erase logo and claim as their own‚Äîunethical)

**Non-Commercial**:
- Resources shared for charitable use only (not for sale‚Äîe.g., Partner can't sell MEF's brochures to other orgs for profit)

**Modifications**:
- Partner may customize shared materials for their audience (e.g., change MEF brochure's phone number to Partner's patient navigator line‚Äîreasonable adaptation)

---

**3. CONFIDENTIALITY**

**Public Resources**: Most shared resources are public-facing (brochures, social media templates)‚Äîno confidentiality restrictions.

**Proprietary Strategies**: If sharing sensitive info (major donor cultivation strategies, Board recruitment plans), recipient treats as confidential (not shared publicly or with other orgs without permission).

---

**4. LIABILITY**

**No Warranties**: Resources provided "as-is" (MEF doesn't guarantee brochure is error-free, Partner doesn't guarantee toolkit will raise $X‚Äîshared in spirit of collaboration, not contractual obligations).

**Liability Waiver**: Each org responsible for its own use (if Partner's event using MEF's Zoom has technical issues, MEF not liable‚ÄîPartner manages their event).

---

**5. TERM**

**Duration**: 24 months (January 1, 2026 - December 31, 2027), renewable by mutual agreement.

**Termination**: Either party may terminate with 30 days notice (cease using shared resources after termination‚Äîdelete CRM accounts, stop distributing brochures).

---

**6. SIGNATURES**

[ED signatures]

---

## Coalition Building

### Joining Rare Disease Coalitions

**Benefits of Coalition Membership**:
- ‚úÖ **Amplified advocacy**: Part of 300+ rare disease orgs lobbying Congress together (Rare Disease Caucus, FDA meetings‚Äîindividual Foundation lacks clout, coalition has political weight)
- ‚úÖ **Shared resources**: Access to legal templates, fundraising webinars, policy toolkits (value: $10K-$20K/year if purchased independently‚Äîcoalition membership $2K-$5K)
- ‚úÖ **Peer learning**: Monthly calls with fellow Executive Directors ("How did you handle X? What's your retention rate?"‚Äîaccelerate Foundation's learning, avoid mistakes others made)
- ‚úÖ **Credibility boost**: NORD member logo on Foundation website (signals professionalism, national reach‚Äîdonors/patients trust more)

---

### Coalition Membership Costs & ROI

**National Organization for Rare Disorders (NORD)**:
- **Membership Dues**: $2,500-$5,000/year (tiered by budget size‚ÄîFoundation's Year 3 budget ~$1M ‚Üí $3,500/year)
- **Benefits**:
  - Rare Disease Database listing (NORD's website‚Äî5M visitors/year, patients searching "AATD" find Foundation)
  - Policy alerts (FDA guidance changes, Congressional bills‚ÄîFoundation stays informed without hiring policy staff)
  - Legal resource library (contracts, employment agreements, IRS compliance guides)
  - Discount programs (insurance, background checks, fundraising platforms‚Äîsave $5K-$10K/year)
- **ROI**: $3,500 membership ‚Üí $10K savings + patient referrals (10-20 patients/year from NORD database‚Äîinvaluable) + policy expertise (equivalent to 0.1 FTE policy staff, ~$10K) ‚Üí **3:1 ROI**

**Global Genes**:
- **Membership Dues**: $1,000-$3,000/year
- **Benefits**:
  - RARE Toolkit (fundraising, awareness, advocacy resources)
  - Educational webinars (monthly‚Äîvolunteer management, major gifts, digital marketing)
  - Rare Disease Day coordination (February 28‚Äînational campaign, social media toolkit, event support)
- **ROI**: $2,000 membership ‚Üí $15K+ value (toolkit saves 20 staff hours designing fundraising materials, webinars = professional development, Rare Disease Day drives 500+ social media engagements) ‚Üí **7:1 ROI**

---

## Joint Advocacy Campaigns

### Legislative Advocacy

**Scenario**: Rare disease organizations want Congress to increase NIH rare disease research funding (currently $4B/year, want $6B).

**Coalition Strategy**:
- **Coordinated Hill visits**: 100 rare disease orgs visit Washington DC same week (Rare Disease Week on Capitol Hill, March)‚Äîeach org meets with their state's Representatives/Senators
- **Unified ask**: All orgs deliver same message ("Support HR 1234‚ÄîRare Disease Research Enhancement Act"‚Äîconsistent talking points, amplified ask)
- **Patient stories**: Mark Egly Foundation brings 2 AATD patients to Capitol Hill (tell Congress about diagnosis delays, treatment costs‚Äîpersonalizes issue)

**Foundation's Role**:
- ‚úÖ Recruit patients for Hill visits (2-4 AATD patients, coach on talking points‚Äî"Tell your story in 3 minutes, emphasize impact of research funding")
- ‚úÖ Draft state-specific fact sheets ("In [State], 1,200 AATD patients‚Äîresearch funding could improve diagnosis rates, treatments")
- ‚úÖ Social media amplification (#RareDiseaseWeek trending‚ÄîFoundation tweets 10√ó/day, tags Congressional offices)

**Outcome**:
- Bill passes (not always‚Äîadvocacy is long game), or increased appropriations in budget ($500M increase‚Äîvictory split among 300+ rare diseases, but AATD gets ~$1M-$2M boost)

---

### Regulatory Advocacy (FDA)

**Scenario**: FDA considering new genetic testing regulations‚Äîcould increase costs, reduce access (bad for AATD patients).

**Coalition Strategy**:
- **Coalition submits comment**: 50 rare disease orgs co-sign letter to FDA ("Proposed regulation will harm patients‚Äîhere's why: X, Y, Z")‚Äîcollective voice harder to ignore than single org
- **Patient testimonies**: FDA holds public hearing‚Äîcoalition coordinates 20 patient testimonies (scheduled slots, diverse diseases, compelling stories‚Äîdemonstrate broad impact)

**Foundation's Contribution**:
- Draft AATD-specific section of comment letter (3-5 pages‚ÄîAATD diagnosis rates, testing costs, patient outcomes data)
- Recruit 1-2 AATD patients to testify at FDA hearing (coach on testimony‚Äîclear, concise, emotional but fact-based)

**Outcome**:
- FDA modifies regulation (incorporates coalition feedback‚Äîexempts rare disease tests from certain requirements)‚Äîpolicy win protecting AATD patients

---

## Patient Data Sharing

### Why Share Patient Data Across Organizations?

**Problem**: Single organization's patient registry has 300-500 patients (statistically underpowered‚Äîcan't detect rare genetic variants, treatment efficacy differences, or subgroup patterns).

**Solution**: Pool data from multiple organizations‚ÄîMark Egly Foundation (500 patients) + Alpha-1 Foundation (2,000 patients) + European partners (3,000 patients) = 5,500-patient dataset ‚Üí detect patterns impossible to see in smaller samples.

---

### Data Sharing Models

**Model 1: Centralized Registry** (All Data in One Database):
- **Structure**: Foundation + 3 partners contribute patient data to shared registry (hosted by neutral party‚Äîacademic institution, NORD)
- **Governance**: Joint steering committee (1 rep from each org) approves data access requests, publications
- **Pros**: ‚úÖ Maximum statistical power, efficient (single database, not duplicating infrastructure)
- **Cons**: ‚ùå Complex governance (4 orgs must agree on decisions‚Äîslow), data security concerns (more parties accessing = more breach risk)

**Model 2: Federated Registry** (Data Stays Siloed, Queries Distributed):
- **Structure**: Each org keeps own patient database‚Äîresearchers submit queries ("How many PI*ZZ patients with FEV1 <50%?"), each org runs query on their data, shares aggregated results (not raw data)
- **Governance**: Each org controls own data (approves queries independently)
- **Pros**: ‚úÖ Data security (patient data never leaves originating org), organizational autonomy preserved
- **Cons**: ‚ùå Less flexible (complex queries require custom coding by each org), slower (sequential queries vs. direct database access)

**Foundation's Choice**: Start with Model 2 (federated‚Äîlower risk, easier governance), consider Model 1 long-term (if trust established, funding secured for centralized platform).

---

### Data Sharing Agreement (Cross-Organization)

**DATA SHARING AGREEMENT**

**Between**: Mark Egly Foundation and [Partner Organization]

---

**1. PURPOSE**

Parties collaborate to advance AATD research by sharing de-identified patient registry data, enabling larger-scale analyses than either org could conduct alone.

---

**2. DATA SCOPE**

**Data Shared**:
- Demographics (age, sex, race/ethnicity, state‚ÄîNO names, addresses, SSNs)
- Genotypes (PI*ZZ, PI*SZ, PI*MZ, etc.)
- Clinical (FEV1, AATD augmentation therapy use, liver disease status)
- Quality of life (SF-36 scores, SGRQ scores)

**Data NOT Shared**:
- Patient identifiable information (names, contact details, medical record numbers)
- Free-text clinical notes (could contain identifiable details)

---

**3. DATA USE**

**Permitted**:
- Joint research projects (approved by both orgs' Scientific Advisory Committees)
- Aggregate reporting (combined statistics‚Äî"In 3,000-patient dataset, 65% are PI*ZZ"‚Äîno individual-level data published)

**Prohibited**:
- Re-identification attempts (combining datasets with external data to identify patients‚Äîstrictly forbidden, contract violation)
- Commercial use (selling data, using for proprietary products‚Äîunethical, illegal without patient consent)

---

**4. GOVERNANCE**

**Joint Data Committee**:
- 2 reps from each org (MEF: ED + CMO, Partner: ED + Research Director)
- Meets quarterly (review data access requests, approve research proposals, resolve disputes)
- Decisions by consensus (if 1 org objects, request denied‚Äîprotects both orgs' interests)

---

**5. PUBLICATION**

**Authorship**: Determined by ICMJE criteria (researchers who substantially contributed to analysis, writing‚Äîorg affiliation doesn't guarantee authorship).

**Acknowledgment**: All publications acknowledge data sources ("Data provided by Mark Egly Foundation and [Partner] patient registries").

**Pre-Publication Review**: Both orgs receive manuscript draft 10 days before submission (check patient privacy, accuracy‚Äîmay not censor unfavorable results).

---

**6. TERM & TERMINATION**

**Term**: 5 years (renewable)

**Termination**: Either party may terminate with 180 days notice (long notice period allows ongoing research projects to complete).

**Data Destruction**: Upon termination, each org deletes other's data (or returns‚Äîrecipient choice), provides written certification of destruction.

---

**7. SIGNATURES**

[ED signatures]

---

## Cross-Promotional Strategies

### Mutual Audience Growth

**Goal**: Expand Foundation's reach by tapping into partner organizations' audiences (email lists, social media followers, event attendees).

---

### Email Newsletter Swaps

**Model**: Foundation mentions partner in monthly newsletter (1 paragraph + link), partner reciprocates.

**Example**:
> **Partner Spotlight: COPD Foundation**
>
> Did you know that COPD and AATD share many symptoms? Our friends at COPD Foundation offer excellent resources for managing breathlessness, pulmonary rehabilitation, and smoking cessation. If you or a loved one has COPD, check out their Patient Resources page: [link].

**Benefits**:
- ‚úÖ Foundation reaches COPD Foundation's 15,000 subscribers (exposure to patients who might have undiagnosed AATD‚Äîgenetic component)
- ‚úÖ Partner reaches Foundation's 3,000 subscribers (AATD patients may have comorbid COPD)
- ‚úÖ Cost: $0 (swapping mentions, not paid ads)

**Frequency**: Quarterly (not every month‚Äîavoid overloading newsletters with partner mentions, focus on own content).

---

### Social Media Shout-Outs

**Model**: Foundation tags partner in social media posts, partner reposts/shares.

**Example**:
> **Facebook Post (Foundation)**:
> "Excited to collaborate with @COPDFoundation on our upcoming webinar about genetic lung diseases! Join us March 15 for expert insights on AATD, CF, and PCD. Register: [link] #RareDisease #LungHealth"
>
> **COPD Foundation Reposts**: Shares Foundation's post to their 10,000 followers‚Äîexponential reach

**Benefits**:
- ‚úÖ Cross-promotion amplifies reach (Foundation's 2,000 followers + Partner's 10,000 = 12,000 total impressions)
- ‚úÖ Builds social proof ("If COPD Foundation partners with Mark Egly Foundation, they must be legit"‚Äîcredibility boost)

**Best Practices**:
- ‚úÖ Tag generously (mention partners often‚Äîthey'll reciprocate)
- ‚úÖ Use partner's hashtags (#COPDChat, #Alpha1Awareness‚Äîincrease discoverability)
- ‚ùå Avoid over-tagging (don't tag 10 orgs in every post‚Äîlooks spammy, dilutes message)

---

### Event Cross-Promotion

**Model**: Foundation promotes partner's events, partner promotes Foundation's events.

**Example**:
- Partner hosts COPD walk (May 1)‚ÄîFoundation posts on Facebook: "Support our partners @COPDFoundation at their annual walk! AATD patients welcome‚Äîregister here: [link]"
- Foundation hosts AATD summit (October 15)‚ÄîPartner emails their list: "Know someone with AATD? Mark Egly Foundation is hosting patient summit‚Äîgreat educational opportunity: [link]"

**Benefits**:
- ‚úÖ Increased event attendance (Foundation's promotion drives 10-20 registrations to partner's walk, partner's promotion drives 15-25 registrations to Foundation's summit‚Äîmutual benefit)
- ‚úÖ Demonstrates collaboration (patients see rare disease orgs working together‚Äîfosters community spirit)

---

## Conflict Resolution

### Common Conflicts in Patient Org Partnerships

**1. Resource Imbalance** ("We're doing all the work, they're coasting"):
- **Example**: Foundation invests 40 hours coordinating joint webinar, partner contributes 5 hours‚ÄîFoundation feels exploited
- **Prevention**: MOU specifies roles clearly (Foundation: logistics 20 hours, partner: speaker recruitment 20 hours‚Äîbalanced)
- **Resolution**: Quarterly check-ins (discuss workload‚Äîif imbalance, renegotiate roles or reduce collaboration scope)

**2. Credit Disputes** ("They're taking credit for our work"):
- **Example**: Partner posts about joint event, only shows their logo (Foundation's logo absent‚Äîappears partner did it alone)
- **Prevention**: MOU includes co-branding requirements ("All joint materials feature both logos, equal size")
- **Resolution**: Foundation emails partner: "We noticed X‚Äîcan you update post to include our logo? Thanks!"‚Äîusually resolved amicably

**3. Mission Drift** ("Partner's priorities changed, no longer aligned"):
- **Example**: Partner pivots from patient advocacy to pharmaceutical consulting (for-profit)‚Äîconflicts with Foundation's nonprofit mission
- **Prevention**: Annual MOU renewal discussion ("Are we still aligned? Should we continue?"‚Äîreassess fit)
- **Resolution**: Amicable separation (terminate MOU, part as friends‚Äî"Your mission evolved, ours stayed same‚Äîno hard feelings")

---

### Dispute Resolution Process

**Step 1: Direct Conversation** (30 Days):
- EDs of both orgs talk (phone or video call‚Äîno lawyers yet)
- Approach: "I'm concerned about X‚Äîcan we discuss?"‚Äîusually resolves 80% of conflicts (miscommunication, not malice)

**Step 2: Mediation** (60 Days):
- Neutral third-party mediator (retired ED of another nonprofit, coalition leader‚Äî$500-$2K)
- Mediator facilitates discussion, proposes compromises‚Äînon-binding (parties accept or decline)

**Step 3: Termination** (If Unresolved):
- Terminate MOU (per terms‚Äî60-90 days notice), cease collaboration
- Maintain professionalism (public statement: "We enjoyed collaborating, but our paths diverge‚Äîwe wish Partner success"‚Äîdon't air dirty laundry)

---

## Partnership Sustainability

### Long-Term Partnership Health

**Success Factors**:
- ‚úÖ **Regular communication**: Quarterly video calls (not just emails‚Äîvoice/video builds relationships, prevents misunderstandings)
- ‚úÖ **Shared wins**: Celebrate successes together ("Our joint webinar had 300 attendees‚Äîhighest ever! Thank you, Partner!"‚Äîpositive reinforcement strengthens bonds)
- ‚úÖ **Flexibility**: Adapt as orgs evolve (Foundation grows, priorities shift‚Äîrenegotiate MOU to reflect new reality)
- ‚úÖ **Trust**: Assume good intent (if partner misses deadline, assume busy/forgot, not malicious‚Äîgive grace)

**Red Flags** (Partnership Deteriorating):
- üö© Communication gaps (partner stops responding to emails‚Äîtakes 2+ weeks, misses quarterly calls)
- üö© Unilateral decisions (partner announces joint project publicly without consulting Foundation‚Äîdisrespectful)
- üö© Resource drain (partnership consumes 20 staff hours/month, yields minimal value‚Äîcost-benefit analysis shows negative ROI)

**When to End Partnership**:
- ‚ö†Ô∏è If red flags persist after 2-3 discussions (Foundation raises concerns, partner doesn't change‚Äîincompatibility)
- ‚ö†Ô∏è If Foundation's capacity limited (better to focus on 2-3 strong partnerships than 10 weak ones‚Äîquality > quantity)

---

## Budget & Resources

### Year 1-3 Budget ($5K-$15K/year)

**Coalition Memberships**:
- NORD membership: $3,000/year
- Global Genes membership: $2,000/year

**Collaboration Expenses**:
- MOU legal review (1-2 MOUs/year, $500-$1,500 each): $1K-$3K
- Joint event costs (Foundation's share‚Äîprinting, catering, travel): $2K-$5K

**Personnel**:
- ED (10% time on partnerships, ~$7K allocation‚Äîattends coalition meetings, negotiates MOUs)

**Total**: $13K-$23K/year

---

### Year 4-7 Budget ($15K-$40K/year)

**Coalition Memberships**:
- NORD, Global Genes, EveryLife Foundation: $6K-$8K/year total

**Collaborations**:
- 3-5 active MOUs (joint events, resource sharing‚Äîshared costs): $10K-$20K/year
- International partnership (data sharing‚Äîtravel to European conference for collaboration meetings): $3K-$5K/year

**Personnel**:
- ED (20% time, ~$14K)
- Patient Advocacy Director (10% time, ~$6K‚Äîmanages day-to-day coalition activities)

**Total**: $33K-$53K/year

---

### Year 8-10 Budget ($40K-$100K/year)

**Coalition Memberships**:
- Expanded (5-7 coalitions‚Äîinternational rare disease orgs, disease-specific alliances): $10K-$15K/year

**Collaborations**:
- 10+ active partnerships (data sharing, joint research, advocacy campaigns): $30K-$60K/year
- Foundation hosts coalition event (annual AATD collaborators summit‚Äîbring together 10-15 partner orgs): $20K-$30K (venue, catering, travel stipends for small orgs)

**Personnel**:
- Partnerships Manager (1.0 FTE, $65K‚Äîdedicated role managing all org-to-org collaborations)
- ED (10% oversight, ~$10K)

**Total**: $125K-$180K/year

---

**Document Owner**: Executive Director & Patient Advocacy Director
**Review Frequency**: Annually (review active partnerships, assess ROI, renew/terminate MOUs)
**Board Oversight**: Board reviews major partnerships (multi-year commitments, financial >$25K) for approval
**Cross-References**:
- Academic Partnership Agreements (Document 29‚Äîresearch collaborations, data sharing parallels)
- Corporate Partnership Contracts (Document 30‚Äîpartnership models, legal structures)
- Data Use Agreement Template (Document 35‚Äîpatient data protection protocols)
- Grant Management Lifecycle (Document 23‚Äîcoalition grant applications)

---

**Last Updated**: November 9, 2025
**Next Review**: November 2026
